Jeremy Castle
Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.
About Jeremy Castle
Starling Oncology, Inc. reported in an 8-K filed May 7, 2025 that Jeremy Castle resigned as Chief Operating Officer, effective May 30, 2025. The proxy statement of Starling Oncology, Inc. reports total compensation of $622,220 for Jeremy Castle in fiscal 2024, including a base salary of $375,000. Disclosed compensation is on record for 2 fiscal years.
“On May 2, 2025, Jeremy Castle provided notice of his resignation as Chief Operating Officer of The Oncology Institute, Inc. (the "Company"), effective as of May 30, 2025.”
Summary generated from SEC filings and earnings-call records held by Equibles.
Affiliation history
Recorded current and former roles; source labels appear when available.
-
Starling Oncology, Inc. (STLN)
Proxy statement
Start not stated–2025-03-27
Last confirmed by a filing; no departure on record
Company network
Recorded roles and call appearances connecting this person to public companies.
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Starling Oncology, Inc. (STLN) | — | $375,000 | $622,220 |
| 2023 | Starling Oncology, Inc. (STLN) | — | $375,000 | $486,126 |
Recent activity
Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.